Immuno-Oncology | Specialty

Expert Discusses Immunotherapy Advances in Head and Neck Cancer

April 25th 2017

Barbara Burtness, MD, discusses her presentation on the current and emerging role of immunotherapy for patients with head and neck cancer.

Expert Highlights Novel Combos, Potential of Immunotherapy in MCL

April 25th 2017

Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.

Dr. Sangro Discusses Safety Profile of Nivolumab in HCC

April 25th 2017

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

Dr. Seiwert on Managing Side Effects for Head and Neck Cancer Treatment

April 25th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.

Immunotherapy Revolutionizes NSCLC, But Unanswered Questions Remain

April 25th 2017

Edward B. Garon, MD discusses the challenges researchers are currently facing with immunotherapy in NSCLC and what the future likely holds for the pivotal agents.

Dr. McDermott on Immunotherapy-Related AEs in RCC

April 24th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.

Exceptional Responder to Pembrolizumab Guides Immunotherapy Progress in Leiomyosarcoma

April 24th 2017

Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.

Dr. Kelley Discusses Biomarkers for Immunotherapy in HCC

April 22nd 2017

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma.

Combination Therapies for Advanced Bladder Cancer

April 22nd 2017

Highlights of Durvalumab for Advanced Bladder Cancer

April 22nd 2017

Use of Immune Checkpoint Inhibitors for Bladder Cancer

April 22nd 2017

Future Treatment Options for Advanced Bladder Cancer

April 22nd 2017

Durvalumab for Treatment of Advanced Bladder Cancer

April 22nd 2017

Immune Checkpoint Inhibitors for Advanced Bladder Cancer

April 22nd 2017

Promising Treatment Options for Advanced Bladder Cancer

April 22nd 2017

FDA Approval of Durvalumab for Advanced Bladder Cancer

April 22nd 2017

Treatment of Bladder Cancer-Immune Checkpoint Inhibitors

April 22nd 2017

FDA Approval of Durvalumab for Bladder Cancer

April 22nd 2017

Frontline Atezolizumab for Advanced Bladder Cancer

April 22nd 2017

Historic Perspective on Bladder Cancer Treatment

April 22nd 2017